NICE’s latest quality standard published today (16 March 2022) helps improve the diagnosis, assessment, and prevention of fetal alcohol spectrum disorder (FASD).
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related sepsis, have been recommended for use by NICE.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
Page 32 of 39
News article listing page, 32 of 39